Compare MOBI & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOBI | ANGO |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.0M | 420.2M |
| IPO Year | 2026 | 2004 |
| Metric | MOBI | ANGO |
|---|---|---|
| Price | $13.02 | $11.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $18.00 | ★ $19.75 |
| AVG Volume (30 Days) | 183.8K | ★ 552.7K |
| Earning Date | 11-05-2026 | 01-05-2027 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $291,010,000.00 |
| Revenue This Year | $71.88 | $5.47 |
| Revenue Next Year | $43.02 | $5.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.17 |
| 52 Week Low | $8.03 | $9.39 |
| 52 Week High | $15.19 | $16.29 |
| Indicator | MOBI | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 67.43 | 38.67 |
| Support Level | $10.55 | $10.57 |
| Resistance Level | $13.85 | $11.66 |
| Average True Range (ATR) | 1.07 | 0.47 |
| MACD | 0.21 | 0.06 |
| Stochastic Oscillator | 86.34 | 0.00 |
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.